Latest filing published 22 Jan 2024 for Invivyd, Inc., €18.2M.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Adimab, LLC: trading record in brief
Adimab, LLC is a declared insider of Invivyd, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 10 August 2021 to 19 January 2024, the count stands at 3 filings.
The open-market record consists of 1 sale worth €18.2M, with no purchase. In 2024 alone, the filings show no purchases and 1 sale.
The latest filing, published on 22 January 2024, reports an open-market sale of €18.2M in Invivyd, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Adimab, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000,000 shares@ US$3.95100.0% of flowCommon StockSEC:0000950170-24-006070:0
- 1,158,089 sharesCommon StockSEC:0000899243-22-013098:0
- 25,860,700 sharesCommon StockSEC:0001209191-21-051295:0
3 of 3 declarations
